VERTEX PHARMACEUTICALS INC / MA Equity Securities, FV-NI, Unrealized Loss
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Equity Securities, FV-NI, Unrealized Loss of $13.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for the quarter ending 2026-06-30 was $8.50M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for the quarter ending 2026-03-31 was $4.60M, a 88.05% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for the quarter ending 2025-12-31 was -$7.20M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for the quarter ending 2025-09-30 was -$16.50M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for fiscal 2024 was $38.50M, a 47.51% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for fiscal 2023 was $26.10M, a 41.08% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for fiscal 2022 was $18.50M, a 230.36% increase from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized loss for fiscal 2021 was $5.60M.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 3 month as first filed | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 6 month as first filed | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $13.10M 10-Q · filed 2026-08-04 | $5.90M derived: sum of 3 quarters · filed 2026-08-04 | -$10.60M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $4.60M 10-Q · filed 2026-05-05 | -$2.60M derived: sum of 2 quarters · filed 2026-08-04 | -$19.10M derived: sum of 3 quarters · filed 2026-08-04 | -$25.50M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | -$7.20M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-04 | -$23.70M derived: sum of 2 quarters · filed 2026-08-04 | -$30.10M derived: sum of 3 quarters · filed 2026-08-04 | $8.40M 10-Q · filed 2026-08-04 | ||
| 2025-09-30 | -$16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$22.90M derived: sum of 2 quarters · filed 2025-11-04 | $15.60M 10-Q · filed 2025-11-04 | $14.50M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2025-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $32.10M 10-Q · filed 2025-08-05 | $31.00M derived: sum of 3 quarters · filed 2026-02-13 | $29.10M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2025-03-31 | $38.50M 10-Q · filed 2025-08-05 | $38.40M 10-Q · filed 2025-05-06 | $37.40M derived: sum of 2 quarters · filed 2026-02-13 | $35.50M derived: sum of 3 quarters · filed 2026-02-13 | $48.30M derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$3.00M derived: sum of 2 quarters · filed 2026-02-13 | $9.80M derived: sum of 3 quarters · filed 2026-02-13 | $38.50M 10-K · filed 2026-02-13 | ||
| 2024-09-30 | -$1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $10.90M derived: sum of 2 quarters · filed 2024-11-05 | $39.60M 10-Q · filed 2024-11-05 | $39.50M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2024-06-30 | $12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $41.50M 10-Q · filed 2024-08-02 | $41.40M derived: sum of 3 quarters · filed 2025-02-13 | $48.10M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2024-03-31 | $28.70M 10-Q · filed 2024-05-07 | $28.60M derived: sum of 2 quarters · filed 2025-02-13 | $35.30M derived: sum of 3 quarters · filed 2025-02-13 | $26.10M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $6.60M derived: sum of 2 quarters · filed 2025-02-13 | -$2.60M derived: sum of 3 quarters · filed 2025-02-13 | $26.10M 10-K · filed 2025-02-13 | ||
| 2023-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.50M derived: sum of 2 quarters · filed 2023-11-07 | $26.20M 10-Q · filed 2023-11-07 | $33.90M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2023-06-30 | -$9.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $19.50M 10-Q · filed 2023-08-02 | $27.20M derived: sum of 3 quarters · filed 2024-02-15 | $27.40M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2023-03-31 | $28.70M 10-Q · filed 2023-05-02 | $36.40M derived: sum of 2 quarters · filed 2024-02-15 | $36.60M derived: sum of 3 quarters · filed 2024-02-15 | $28.70M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $7.90M derived: sum of 2 quarters · filed 2024-02-15 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | $18.50M 10-K · filed 2024-02-15 | ||
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$7.70M derived: sum of 2 quarters · filed 2022-10-28 | $10.80M 10-Q · filed 2022-10-28 | $15.48M derived: sum of 4 quarters · filed 2023-05-02 | ||
| 2022-06-30 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $10.60M 10-Q · filed 2022-08-05 | $15.28M derived: sum of 3 quarters · filed 2023-05-02 | $10.60M derived: sum of 4 quarters · filed 2023-05-02 | ||
| 2022-03-31 | $18.50M 10-Q · filed 2023-05-02 | $6.30M 10-Q · filed 2022-05-06 | $23.18M derived: sum of 2 quarters · filed 2023-05-02 | $18.50M derived: sum of 3 quarters · filed 2023-05-02 | $24.10M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2021-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $0.00 derived: sum of 2 quarters · filed 2023-02-10 | $5.60M derived: sum of 3 quarters · filed 2023-02-10 | $5.60M 10-K · filed 2023-02-10 | ||
| 2021-09-30 | -$4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $917.00K derived: sum of 2 quarters · filed 2022-05-06 | $917.00K 10-Q · filed 2021-11-03 | $917.00K derived: sum of 4 quarters · filed 2022-05-06 | ||
| 2021-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $5.60M 10-Q · filed 2022-05-06 | $0.00 10-Q · filed 2021-07-30 | $5.60M derived: sum of 3 quarters · filed 2022-05-06 | $5.60M derived: sum of 4 quarters · filed 2022-05-06 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-30 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $0.00 derived: sum of 4 quarters · filed 2022-02-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $0.00 10-K · filed 2022-02-09 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $0.00 derived: sum of 2 quarters · filed 2020-10-30 | $0.00 10-Q · filed 2020-10-30 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-01 | |||||
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |